Surveillance Underused in Colorectal Cancer Survivors

Share this content:
There continues to be substantial underuse of surveillance for survivors of colorectal cancer, particularly for stage II patients.
There continues to be substantial underuse of surveillance for survivors of colorectal cancer, particularly for stage II patients.

There continues to be substantial underuse of surveillance for survivors of colorectal cancer, particularly for stage II patients, a new study published online ahead of print in the journal Cancer has shown.

For the study, researchers conducted a retrospective analysis of 23,990 patients with colon cancer and 5,665 patients with rectal cancer who were identified in the Survival, Epidemiology, and End Results (SEER)-Medicare database. All patients had undergone resection of stage I to III colorectal cancer between 2001 and 2009.

Results showed that rates of office visits and colonoscopy were high and stable over the study period, while rates of carcinoembryonic antigen (CEA) testing remained low despite increasing, even for patients with stage III disease.

Researchers found that rates of CT imaging gradually increased over the study period, but the 2005 guideline change to include recommendations for CT surveillance in select patients had no effect.

RELATED: Addition of Selective Radiation Improves Liver Survival in Colorectal Cancer Metastases

Despite similar guideline recommendations, patients with stage II disease, including those at high-risk, received surveillance at significantly lower rates than those with stage III disease.

Furthermore, the study showed that up to 30% of patients with stage I colorectal cancer underwent nonrecommended CEA testing and CT imaging.

Reference

  1. Paulson EC, Veenstra CM, Vachani A, et al. Trends in surveillance for resected colorectal cancer. Cancer. 2015. [Epub ahead of print]. doi: 10.1002/cncr.29469.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters